New York Life Investment Management’s Pacira BioSciences PCRX Stock Holding History

New York Life Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,507	Closed	-$365K	–	1185
2024 Q1	$365K	Buy	12,507 +3,980	+47%	+$122K	﹤0.01%	1095
2023 Q4	$288K	Sell	8,527 -197	-2%	-$5.76K	﹤0.01%	1234
2023 Q3	$268K	Sell	8,724 -1,375	-14%	-$49.6K	﹤0.01%	1221
2023 Q2	$405K	Sell	10,099 -1,488	-13%	-$61.5K	﹤0.01%	986
2023 Q1	$473K	Buy	+11,587	New	+$461K	0.01%	1039

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's PCRX Position: Q2 2024 in Review

New York Life Investment Management sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 12,507 shares — an estimated $365K sold.

New York Life Investment Management first reported a position in PCRX in Q1 2023 and held it in 5 quarters. The position peaked at $473K in Q1 2023. 281 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

New York Life Investment Management reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
New York Life Investment Management sold 12,507 Pacira BioSciences shares in Q2 2024, an estimated $365K.
New York Life Investment Management first reported a position in Pacira BioSciences in Q1 2023 and held it in 5 quarters.
New York Life Investment Management's Pacira BioSciences position peaked at $473K in Q1 2023.
281 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.